MedTrace Logo

Regorafenib Post-marketing Surveillance

NCT01843400 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1301

Last updated 2018-08-02

No results posted yet for this study

Summary

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for colorectal cancer.

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice.

A total of 1,250 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

Patients treated with Regorafenib under practical manner for colorectal cancer.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-22
Primary Completion
2016-09-12
Completion
2016-11-14

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01843400 on ClinicalTrials.gov